Fama and French published their three-factor model in 1992. Size and value, they showed, were priced risk factors — meaning small-cap value stocks should, in aggregate, outperform large-cap growth stocks over sufficiently long periods. The excess return historically ran about 4% annually.
Then came 2009-2023. Small-cap value trailed the S&P 500 by approximately 5% annualized for 14 consecutive years. Investors who tilted toward the factor based on Fama-French research saw their portfolios substantially underperform simple total market index funds. The factor premium either died, disappeared, or is the longest drawdown in its history.
What Is Small-Cap Value
Small-cap means bottom 10-20% of the US equity market by market capitalization — companies under roughly $4 billion in market value. Value means trading at low price-to-book or price-to-earnings multiples relative to peers. Small-cap value is the intersection: smaller companies that are also relatively cheap.
Fama and French hypothesized that these stocks carry more risk — they're more volatile, more likely to go bankrupt, more sensitive to economic shocks. Rational investors should demand higher expected returns for bearing that risk. Historical data confirmed this: from 1926 to 2000, small-cap value crushed every other equity subset.
The Two Small-Cap Value ETFs Worth Considering
Avantis US Small Cap Value (AVUV): Launched 2019. 0.25% expense ratio. Uses a multi-factor approach — small, value, profitability. About 700 holdings. This is what most factor-investing academics recommend for retail investors.
Vanguard Small-Cap Value ETF (VBR): 0.07% expense ratio. Broader holdings, less pure factor exposure. About 830 stocks. Tracks the CRSP US Small Cap Value Index.
AVUV has a tighter factor tilt and slightly better recent performance. VBR is cheaper and more diversified. For a small-cap value tilt, AVUV is usually the better choice — but VBR is defensible if you're fee-conscious.
The Case for Tilting Toward Small-Cap Value
Fama-French data still shows the factor premium exists over 40+ year windows. The 14-year underperformance is large, but not unprecedented — the mid-1990s saw a similar stretch before small-cap value rallied hard in 2000-2007.
Current valuations favor the factor. Small-cap value trades at a P/E ratio of roughly 12. Large-cap growth (dominated by tech) trades at P/E 28-32. The valuation spread is near its widest in 40 years. If mean reversion matters at all, the starting point favors small-cap value today.
Factor premia have always arrived in lumpy, unpredictable bursts. Investors who sat out 2000-2007 because small-cap value had underperformed 1995-1999 missed the biggest outperformance period on record. Pattern recognition here is adversarial — the factor works least well right before it works most.
The Case Against
Factor exposure is more theoretical than actionable. After transaction costs, tax drag, and higher expense ratios, the paper premium of 4% becomes perhaps 2-2.5% real-world — if it still exists at all.
The factor may have been arbitraged away. Once every institutional allocator read Fama-French, money flowed into small-cap value ETFs. The flow itself bid up prices, reducing future returns. Some academic work suggests factor premia have been halved since the research went mainstream.
Behavioral risk is enormous. Tilting 20% of your portfolio to small-cap value means watching it underperform the market by 5% for years. Most investors can't hold through that — they capitulate at the bottom, often locking in permanent losses.
Survivorship and Sample Size
The historical small-cap value premium was measured in one country (US), over one period (roughly 80 years). Out-of-sample tests in other countries show mixed results. The UK, Japan, and European small-cap value have performed inconsistently. If the US data was a statistical anomaly rather than a persistent risk premium, betting on it now is a mistake.
Conversely: if the premium is real, 80 years isn't actually that much data. A 15-year drawdown is consistent with that kind of factor over that kind of window.
How Much to Tilt
Defensible allocations if you decide to tilt:
- 5-10% small-cap value: Minor tilt. Most of portfolio remains total market. Low regret risk.
- 15-20% small-cap value: Meaningful factor exposure. Real tracking error vs. market.
- 25%+ small-cap value: Pure factor bet. Only makes sense for investors who genuinely understand factor investing and have held through full cycles before.
The Larry Swedroe argument: if you tilt, tilt meaningfully. A 3% allocation doesn't move the needle. The diversification benefit of small-cap value comes from it behaving differently than the market, which only matters if it's a material piece of your portfolio.
The Integration Problem
If you own VTI, you already own small-cap value stocks — they're just a small percentage of the fund (maybe 3-4%). Adding AVUV doesn't give you exposure you lack. It overweights a segment you already have.
Overlapping holdings are fine if you understand what you're doing. A 15% AVUV + 85% VTI portfolio has small-cap value at roughly 18% total — meaningful tilt. A 5% AVUV + 95% VTI portfolio has small-cap value at 8% total — barely different from the market.
The Practical Verdict
Small-cap value factor investing is legitimate. It's also emotionally brutal and mathematically uncertain. For most retail investors, a three-fund portfolio without factor tilts is the right answer. For investors who've held equity portfolios through at least two major cycles and genuinely understand factor investing, a 10-20% AVUV allocation is defensible.
The worst outcome is buying AVUV now because it "should" work, then selling after another two years of underperformance, right before it finally rallies. That's not a factor strategy — it's buy high, sell low, wearing academic clothes.
If you can't imagine holding AVUV for 20 years through any pattern of relative performance, don't buy it. The factor works only for investors who can commit to the discipline the theory requires.